Company profile for ProtoKinetix

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

ProtoKinetix (PKTX) is a research and development company leading the way in cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide helps more cells survive...
ProtoKinetix (PKTX) is a research and development company leading the way in cell survival solutions. Its patented anti-aging glycopeptide (AAGP) is a revolutionary discovery with incredible opportunity to shape the future of ophthalmology, dermatology, transplant support and biomanufacturing. Based on a molecule found in nature and harnessed by a world-class research team, this anti-aging glycopeptide helps more cells survive longer and has the capability to change health care forever.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
412 Mulberry St. Marietta, Ohio 45750
Telephone
Telephone
740-434-5041
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20220720005086/en

BUSINESSWIRE
20 Jul 2022

https://www.catalent.com/catalent-news/protokinetix-announces-selection-of-aagp-candidate-formulations-for-treatment-of-dry-eye-disease/

PRESS RELEASE
23 Nov 2021

https://www.catalent.com/catalent-news/protokinetix-announces-selection-of-aagp-candidate-formulations-for-treatment-of-dry-eye-disease/

PRESS RELEASE
23 Nov 2021

https://www.businesswire.com/news/home/20210512005144/en/ProtoKinetix-and-IQVIA-Partner-to-Support-Development-of-AAGP%C2%AE-Product-in-the-Treatment-of-Ocular-Conditions

BUSINESSWIRE
12 May 2021

https://www.businesswire.com/news/home/20210422005429/en/ProtoKinetix-Announces-the-Resumption-of-Phase-1b-Clinical-Trials-for-the-use-of-AAGP%C2%AE-Treated-Islet-Cells-in-the-Treatment-of-Type-1-Diabetes

BUSINESSWIRE
22 Apr 2021

https://www.businesswire.com/news/home/20201124005302/en/Research-Paper-Showing-ProtoKinetix-AAGP%C2%AE-Enhanced-Stem-Cell-Derived-Retina-Precursor-Cells-Restoration-of-Vision

BUSINESSWIRE
24 Nov 2020

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty